What Pregnancy Antidepressants Do to a Baby's Brain

What Antidepressants During Pregnancy Do to a Baby's Brain

Millions of pregnant people take antidepressants — scientists are now asking what, if anything, that leaves behind in the baby's brain.

Using repeated brain scans of children over time — from large population-based cohort studies — researchers asked whether being exposed to SSRIs in the womb changes how the brain develops. SSRIs (selective serotonin reuptake inhibitors) are the most commonly prescribed antidepressants: the category that includes fluoxetine and sertraline. They found subtle differences in brain structure, particularly in regions called corticolimbic areas — the brain's emotional regulation machinery, roughly the structures that process fear, attachment, and stress. Think of the developing brain like wet concrete: anything that touches it while it's setting can leave a small impression. SSRIs appear to leave one. Here is what matters most: many of those differences faded over time. The brain adapted — a property researchers call plasticity, meaning its ability to reshape itself as it grows. That is not nothing. Why does this matter? Roughly one in ten pregnant people takes antidepressants. For many, stopping is not a safe option — untreated depression in pregnancy carries its own serious risks for both mother and child. This research does not say stop. It says: keep watching. The catch is real. This is observational research — you cannot randomly assign someone to take SSRIs or not. Separating the effect of the drug from the effect of the underlying depression is genuinely hard. The researchers also found that maternal depressive symptoms themselves were linked to differences in child neurodevelopment, with different patterns from those linked to medication. Untangling drug from disease remains the central unsolved problem here.

People Who Grew Up in Foster Care Are Still Struggling at 40

Most attention on foster care clusters around teenagers aging out — this review asks what their lives actually look like thirty years later.

Researchers conducted a scoping review — a systematic sweep of existing literature — covering 29 studies that tracked the health of adults who grew up in state care: foster homes, group homes, residential settings. The question was simple: what happens after 30? In 28 of those 29 studies, care-experienced adults showed higher rates of mental health problems than the general population. Twelve studies also documented higher rates of physical health problems. Think of the care system like a relay race where the baton gets handed off at 18. You are told to run. What this review shows is that decades later, many people are still stumbling from that handoff. Why does this matter? Policy and clinical attention tends to cluster around the transition out of care — at 16, 18, or 21. This review is evidence that the consequences of early instability do not expire. Mental health difficulties appear to persist well into middle age. There are millions of care-experienced adults, and most health systems do not see them as a group with specific needs. The catch the researchers name themselves: most studies blurred together two different populations — people who formally aged out of care at 18, and all adults who had any care experience, including those who reunited with families or were adopted. That distinction matters enormously for understanding who faces the highest risk. So we know the outcome is worse. We do not yet know precisely who is most at risk or exactly why — and that gap is a methodological problem the field has not yet fixed.

Hot Flashes Plus Depression Costs Midlife Women Nearly Twice as Much

Six thousand dollars a year if you have neither condition — eleven thousand if you have both hot flashes and depression at the same time.

Researchers pooled data from the US Medical Expenditure Panel Survey — a large ongoing government survey tracking what Americans actually spend on healthcare — covering 2017 to 2022. They looked at midlife women divided into three groups: those with neither condition, those with vasomotor symptoms alone, and those with both vasomotor symptoms and depression. Vasomotor symptoms — the official term for hot flashes and night sweats during menopause — affect roughly three in four women going through this transition, sometimes severely. The numbers are stark. Women with vasomotor symptoms alone spent $9,303 per year on average. Women with both conditions spent $11,404. Women with neither spent $6,002. Prescription drug costs for the combined group were 2.61 times higher. Think of it like a utility bill: a hot climate already costs more than a mild one — but if your home's temperature regulation system is also broken, you end up paying on two fronts simultaneously. Why does this matter beyond the dollar figures? It suggests that when depression and menopause symptoms land on the same person at the same time — which happens frequently, since the hormonal upheaval of menopause is a known risk factor for depression — treating each condition separately may be both clinically and financially inefficient. The overlap is not a coincidence. The honest catch: this is a cross-sectional study — a snapshot, not a film. It shows costs are higher but cannot tell us whether treating depression reduces the severity of hot flashes, or vice versa. And insurance claims data misses uninsured and underinsured women, who may carry an even heavier burden.

Here is the thread connecting today's three stories: mental health does not stay in one place, and the systems meant to address it keep missing it. The pregnancy study says: the brain starts being shaped before birth — by depression itself, and possibly by the drugs we use to treat it. We cannot cleanly separate the two yet. The care leavers review says: childhood instability echoes into middle age, but health systems are largely not tracking care-experienced adults as a distinct group with distinct needs. The menopause cost study says: when depression and a hormonal transition collide in the same person, the impact multiplies — yet clinical guidelines still tend to treat them as separate problems. Taken together, these three papers are a reminder that mental health is a lifelong story. Treating a single episode, in a single clinic, at a single age, is a necessary start — but it is not the whole picture.

The perinatal SSRI question will sharpen as children whose mothers took antidepressants in the early 2010s enter their teenage years — the ABCD Study in the US and the Generation R cohort in the Netherlands are both tracking exactly this, and longer follow-up data is due in the next few years. On the menopause-depression intersection, clinical guidelines from NICE in the UK and ACOG in the US are both under active review; any updated recommendations on menopausal hormone therapy and depression screening would speak directly to what this cost study is measuring.

• Wikipedia: Antidepressants and pregnancy — background on SSRIs and prenatal exposure
• Wikipedia: Foster care — overview of the care system and long-term outcomes
• Wikipedia: Menopause — context on vasomotor symptoms and hormonal changes